{"id":"xyrem","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"20%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"15%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Somnolence","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Enuresis","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Tremor","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Feeling drunk","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Disturbance in attention","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Disorientation","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Sleepwalking","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Irritability","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Sleep paralysis","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Paresthesia","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Hyperhidrosis","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Muscle spasms","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Anxiety","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Abdominal pain upper","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Dry mouth","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Pain in extremity","drugRate":"1%","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Alcohol intoxication","Alcoholism","Chronic heart failure","Chronic lung disease","Decreased respiratory function","Depressive disorder","Disease of liver","Hypertensive disorder","Impaired cognition","Incontinence of feces","Psychiatric Disturbance","Seizure disorder","Sleep apnea","Sleep walking disorder","Substance abuse","Succinate-semialdehyde dehydrogenase deficiency","Suicidal thoughts","Urinary incontinence"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Treatment discontinuation due to adverse reactions","drugRate":"10.3%","severity":"serious"},{"effect":"Respiratory depression","drugRate":"","severity":"serious"},{"effect":"Abuse and dependence","drugRate":"","severity":"serious"},{"effect":"CNS depression","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1200682","moleculeType":"Small molecule","molecularWeight":"126.09"},"aliases":["Sodium Oxybate","Sodium Oxybate Placebo","gamma-hydroxybutyrate"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Xyrem","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:07:24.760201+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:07:30.875236+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xyrem","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:07:31.487276+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: GABA-B receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:07:32.526353+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200682/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:07:32.184790+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"926eb076-a4a8-45e4-91ef-411f0aa4f3ca","title":"XYREM (SODIUM OXYBATE) SOLUTION [JAZZ PHARMACEUTICALS, INC.]"},"ecosystem":[],"mechanism":{"target":"Calcium/calmodulin-dependent protein kinase type II subunit alpha, GABA-B receptor, Gamma-hydroxybutyrate receptor"},"_scrapedAt":"2026-03-28T00:16:21.701Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:07:33.819304+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Cataplexy and narcolepsy","diseaseId":"cataplexy-and-narcolepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Narcolepsy","diseaseId":"narcolepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06421532","phase":"PHASE2","title":"Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy","status":"ENROLLING_BY_INVITATION","sponsor":"Leiden University Medical Center","startDate":"2025-03-27","conditions":"Cerebral Amyloid Angiopathy","enrollment":60},{"nctId":"NCT06525077","phase":"PHASE3","title":"Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avadel","startDate":"2024-08-01","conditions":"Idiopathic Hypersomnia","enrollment":150},{"nctId":"NCT05085873","phase":"PHASE4","title":"Sodium Oxybate Versus Midazolam for Comfort Sedation","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2021-10-14","conditions":"Palliative Care","enrollment":22},{"nctId":"NCT03292458","phase":"PHASE2, PHASE3","title":"Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor","status":"COMPLETED","sponsor":"Kristina Simonyan","startDate":"2018-01-22","conditions":"Spasmodic Dysphonia, Voice Tremor","enrollment":117},{"nctId":"NCT07041203","phase":"PHASE1","title":"Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor","status":"NOT_YET_RECRUITING","sponsor":"Kristina Simonyan","startDate":"2026-03-01","conditions":"Spasmodic Dysphonia, Laryngeal Dystonia, Voice Tremor","enrollment":8},{"nctId":"NCT06950281","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Low Sodium Oxybate for Nocturnal Cluster Headache Attacks","status":"NOT_YET_RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2026-01","conditions":"Chronic Cluster Headache","enrollment":52},{"nctId":"NCT06809803","phase":"PHASE2","title":"Extended-release Sodium Oxybate in Children","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-10-27","conditions":"Narcolepsy Type 1 (NT 1)","enrollment":36},{"nctId":"NCT04451668","phase":"PHASE3","title":"An Open Label Study of FT218 in Subjects With Narcolepsy","status":"COMPLETED","sponsor":"Avadel","startDate":"2020-06-12","conditions":"Narcolepsy, Cataplexy, Excessive Daytime Somnolence","enrollment":184},{"nctId":"NCT05536011","phase":"","title":"WAKIX® (Pitolisant) Pregnancy Registry","status":"RECRUITING","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2021-08-24","conditions":"Pregnancy Related, Narcolepsy","enrollment":1329},{"nctId":"NCT07077278","phase":"PHASE4","title":"Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-10-01","conditions":"Idiopathic Hypersomnia, POTS - Postural Orthostatic Tachycardia Syndrome","enrollment":25},{"nctId":"NCT05875974","phase":"PHASE4","title":"A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2023-07-27","conditions":"Idiopathic Hypersomnia, Narcolepsy","enrollment":207},{"nctId":"NCT05837091","phase":"PHASE4","title":"Low Sodium Oxybate in Patients With Idiopathic Hypersomnia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-02-14","conditions":"Idiopathic Hypersomnia","enrollment":30},{"nctId":"NCT05869773","phase":"PHASE4","title":"A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2023-06-26","conditions":"Narcolepsy","enrollment":160},{"nctId":"NCT04224246","phase":"PHASE2","title":"Impact of Gamma-OH on Sleep in ICU Patients","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2020-02-27","conditions":"Weaning from Mechanical Ventilation","enrollment":20},{"nctId":"NCT04794582","phase":"NA","title":"Prevention of Incisional Hernia After Renal Transplantation","status":"RECRUITING","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2022-08-31","conditions":"Incisional Hernia, Kidney Transplantation, Postoperative Complications","enrollment":160},{"nctId":"NCT06137599","phase":"","title":"GCS Survey: \"GHB IN CHEMICAL SUBMISSION: MYTH OR REALITY?\"","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-20","conditions":"CHEMICAL SUBMISSION","enrollment":200},{"nctId":"NCT04794491","phase":"PHASE4","title":"An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2021-03-22","conditions":"Narcolepsy","enrollment":62},{"nctId":"NCT03597555","phase":"PHASE2, PHASE3","title":"Sodium Oxybate in Idiopathic Hypersomnia","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2018-10-18","conditions":"Idiopathic Hypersomnia","enrollment":48},{"nctId":"NCT04006925","phase":"PHASE4","title":"Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-09-10","conditions":"REM Sleep Behavior Disorder, Parkinson Disease","enrollment":24},{"nctId":"NCT01584934","phase":"PHASE4","title":"Sodium Oxybate in Patients With Chronic Fatigue Syndrome.","status":"WITHDRAWN","sponsor":"University Hospital, Ghent","startDate":"2013-06","conditions":"Chronic Fatigue Syndrome","enrollment":""},{"nctId":"NCT00641186","phase":"PHASE2","title":"Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-09","conditions":"Parkinson Disease","enrollment":30},{"nctId":"NCT04508166","phase":"NA","title":"Towards a Post-exposition Pharmacological Prophylaxis for Post-traumatic Stress Disorder","status":"COMPLETED","sponsor":"Psychiatric University Hospital, Zurich","startDate":"2021-10-01","conditions":"Intrusive Thought, Psychological Trauma, Inflammatory Response","enrollment":27},{"nctId":"NCT04803786","phase":"","title":"A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2021-04-09","conditions":"Narcolepsy","enrollment":110},{"nctId":"NCT04082806","phase":"PHASE2","title":"Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder.","status":"COMPLETED","sponsor":"Erich Seifritz","startDate":"2020-08-06","conditions":"Major Depressive Disorder","enrollment":54},{"nctId":"NCT00345800","phase":"PHASE1","title":"Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2006-04-10","conditions":"Narcolepsy With Cataplexy","enrollment":25},{"nctId":"NCT02720744","phase":"PHASE3","title":"Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy","status":"COMPLETED","sponsor":"Avadel","startDate":"2016-11-17","conditions":"Excessive Daytime Sleepiness, Cataplexy, Narcolepsy","enrollment":212},{"nctId":"NCT02637076","phase":"PHASE4","title":"Xyrem and Brain Dopamine in Narcolepsy","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2016-01","conditions":"Narcolepsy With Cataplexy, Healthy Controls","enrollment":17},{"nctId":"NCT03626727","phase":"EARLY_PHASE1","title":"Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2020-09","conditions":"Hypersomnia, Narcolepsy, Traumatic Brain Injury","enrollment":""},{"nctId":"NCT02111122","phase":"PHASE2","title":"Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease","status":"COMPLETED","sponsor":"Christian Baumann","startDate":"2014-04","conditions":"Sleep-wake Disturbances in Motor-phase Parkinson's Disease","enrollment":16},{"nctId":"NCT04648423","phase":"PHASE4","title":"Evaluation of the Efficacy of Sodium Oxybate in the Long-term Maintenance of Abstinence in Alcoholic Patients","status":"COMPLETED","sponsor":"Laboratorio Farmaceutico Ct S.r.l.","startDate":"2001-07-23","conditions":"Alcohol Use Disorder (AUD), Alcohol Dependence","enrollment":314},{"nctId":"NCT02055898","phase":"PHASE4","title":"SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2014-04","conditions":"Chronic Fatigue Syndrome","enrollment":13},{"nctId":"NCT03030599","phase":"PHASE3","title":"A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2017-03-14","conditions":"Narcolepsy With Cataplexy","enrollment":201},{"nctId":"NCT04322214","phase":"PHASE1","title":"Clinical Trial to Evaluate Pharmacological Interactions Between γ-hydroxybutyrate (GHB) and Cobicistat","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2020-01-30","conditions":"Pharmacokinetic Interactions, HIV","enrollment":12},{"nctId":"NCT02342366","phase":"NA","title":"Characterization of the Prosocial and Prosexual Effects of GHB","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2012-02","conditions":"Depressive Disorder, Major, Bipolar Disorder, Autistic Disorder","enrollment":19},{"nctId":"NCT02221869","phase":"PHASE3","title":"A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2014-10-01","conditions":"Narcolepsy With Cataplexy","enrollment":106},{"nctId":"NCT02063217","phase":"NA","title":"Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-12","conditions":"Amyloid-beta","enrollment":36},{"nctId":"NCT00744393","phase":"PHASE2","title":"The Effect of Sodium Oxybate on Sleep Architecture","status":"WITHDRAWN","sponsor":"Tufts Medical Center","startDate":"2008-10","conditions":"Mechanically Ventilated ICU Patients","enrollment":""},{"nctId":"NCT01961297","phase":"PHASE2","title":"Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response","status":"COMPLETED","sponsor":"Kristina Simonyan","startDate":"2012-07","conditions":"Spasmodic Dysphonia, Voice Tremor","enrollment":53},{"nctId":"NCT00383643","phase":"PHASE2","title":"Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-05","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":48},{"nctId":"NCT00244465","phase":"","title":"Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-05","conditions":"Narcolepsy","enrollment":750},{"nctId":"NCT00498485","phase":"PHASE4","title":"Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome","status":"TERMINATED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2007-05","conditions":"Chronic Fatigue Syndrome","enrollment":17},{"nctId":"NCT00594256","phase":"PHASE2","title":"Sodium Oxybate in Schizophrenia With Insomnia","status":"COMPLETED","sponsor":"Nathan Kline Institute for Psychiatric Research","startDate":"2008-05","conditions":"Schizophrenia, Insomnia Related to Schizophrenia (307.42)","enrollment":8},{"nctId":"NCT02637648","phase":"PHASE3","title":"Sodium Oxybate in Patients With Episodic and Chronic Cluster Headache","status":"UNKNOWN","sponsor":"Ramin Khatami","startDate":"2015-12","conditions":"Cluster Headache","enrollment":60},{"nctId":"NCT01789398","phase":"PHASE3","title":"Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)","status":"COMPLETED","sponsor":"Bioprojet","startDate":"2012-09","conditions":"Narcolepsy","enrollment":51},{"nctId":"NCT02215499","phase":"PHASE1","title":"A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics","status":"COMPLETED","sponsor":"Concert Pharmaceuticals","startDate":"2014-07","conditions":"Narcolepsy, Excessive Daytime Sleepiness","enrollment":28},{"nctId":"NCT00931164","phase":"PHASE1, PHASE2","title":"Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)","status":"COMPLETED","sponsor":"University of Utah","startDate":"2009-08","conditions":"Alternating Hemiplegia of Childhood","enrollment":6},{"nctId":"NCT02090504","phase":"PHASE4","title":"Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2002-02","conditions":"Alcohol Withdrawal Syndrome, Alcohol Dependence","enrollment":127},{"nctId":"NCT00132873","phase":"PHASE3","title":"Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2004-10","conditions":"Narcolepsy","enrollment":59},{"nctId":"NCT00330291","phase":"PHASE2","title":"Xyrem for Treatment Refractory Insomnia Due to PTSD","status":"WITHDRAWN","sponsor":"State University of New York - Upstate Medical University","startDate":"2005-08","conditions":"PTSD, Anxiety, Post Traumatic","enrollment":""},{"nctId":"NCT00423605","phase":"PHASE3","title":"Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2006-12","conditions":"Fibromyalgia","enrollment":560},{"nctId":"NCT00086281","phase":"PHASE4","title":"Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2003-11","conditions":"Obstructive Sleep Apnea Syndrome","enrollment":60},{"nctId":"NCT00423813","phase":"PHASE3","title":"A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2006-12","conditions":"Fibromyalgia","enrollment":573},{"nctId":"NCT00087555","phase":"PHASE2","title":"Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2004-07","conditions":"Fibromyalgia","enrollment":195},{"nctId":"NCT00598078","phase":"PHASE2","title":"Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2007-12","conditions":"Essential Tremor","enrollment":19},{"nctId":"NCT00371137","phase":"PHASE3","title":"A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2006-08","conditions":"Fibromyalgia","enrollment":548},{"nctId":"NCT00066170","phase":"PHASE3","title":"Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2003-04","conditions":"Narcolepsy","enrollment":231},{"nctId":"NCT00803023","phase":"PHASE3","title":"Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2010-03","conditions":"Fibromyalgia","enrollment":129},{"nctId":"NCT00514995","phase":"PHASE2, PHASE3","title":"Sodium Oxybate in the Treatment of Binge Eating Disorder","status":"COMPLETED","sponsor":"Lindner Center of HOPE","startDate":"2007-08","conditions":"Binge Eating Disorder","enrollment":15},{"nctId":"NCT00706186","phase":"PHASE4","title":"Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients","status":"TERMINATED","sponsor":"Clayton Sleep Insititute","startDate":"","conditions":"Mild Alzheimer's Disease","enrollment":4},{"nctId":"NCT00506974","phase":"PHASE4","title":"Enhancing Slow Wave Sleep With Sodium Oxybate","status":"COMPLETED","sponsor":"St. Luke's Hospital, Chesterfield, Missouri","startDate":"2007-05","conditions":"Sleep","enrollment":60},{"nctId":"NCT00058955","phase":"PHASE1","title":"Physiological, Behavioral and Subjective Effects of Drugs (GHB)","status":"COMPLETED","sponsor":"Orphan Medical","startDate":"2003-08","conditions":"Sedative Abuse","enrollment":20},{"nctId":"NCT00049803","phase":"PHASE3","title":"Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients","status":"COMPLETED","sponsor":"Orphan Medical","startDate":"2000-12","conditions":"Narcolepsy","enrollment":200}],"_emaApprovals":[],"_faersSignals":[{"count":4313,"reaction":"NAUSEA"},{"count":3669,"reaction":"ANXIETY"},{"count":3186,"reaction":"SOMNOLENCE"},{"count":3048,"reaction":"DEPRESSION"},{"count":2951,"reaction":"HEADACHE"},{"count":2926,"reaction":"FEELING ABNORMAL"},{"count":2861,"reaction":"CONDITION AGGRAVATED"},{"count":2831,"reaction":"WEIGHT DECREASED"},{"count":2701,"reaction":"FATIGUE"},{"count":2642,"reaction":"DIZZINESS"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1200682"},"formularyStatus":[],"_approvalHistory":[{"date":"20250728","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20020717","type":"ORIG","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20241118","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20211209","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20240522","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20210812","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20171116","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20230404","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20200721","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20170419","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20220822","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20131220","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20200925","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20181026","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20150817","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20060630","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20150223","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20061113","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20050916","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20051118","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20250521","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20220209","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20031104","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20240116","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20210211","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20170126","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20140411","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20200721","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20160623","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20190509","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20150715","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20150227","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"},{"date":"20121217","type":"SUPPL","sponsor":"JAZZ PHARMS","applicationNumber":"NDA021196"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":82,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Xyrem","genericName":"Xyrem","companyName":"Jazz Pharmaceuticals","companyId":"jazz-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:07:33.819304+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}